The upcoming presentations focus on critical markers of long-term patient health, including joint preservation, bleeding control, and perioperative management. Researchers will share findings from both clinical trials and observational studies, aiming to address the evolving needs of individuals navigating haemophilia A and B. According to Dr. Lydia Abad-Franch, Sobi’s Chief Medical Officer, the data underscore a broader effort to refine treatment standards through a combination of rigorous clinical development and real-world performance tracking.
Sobi to Present New Haemophilia Data at ISTH 2026 Congress
Sobi will unveil a series of clinical analyses and real-world evidence for its haemophilia portfolio at the International Society on Thrombosis and Haemostasis congress in Paris. From 11–15 July 2026, the company plans to showcase outcomes for its flagship therapies, Altuvoct, Elocta, and Alprolix, across diverse patient populations.
Key updates include interim results from the FREEDOM and XTEND-ed studies regarding the use of efanesoctocog alfa, alongside reports on the effectiveness of Elocta and Alprolix in varied clinical settings. The findings are expected to provide physicians with additional clarity on optimizing prophylactic regimens and improving quality of life for patients managed through these specialized therapies.
Comments (0)
No comments yet. Be the first!